Home > News > Headline News


Please Note

Some news stories may require you to register or sign in.  MedPage, for example, has an easy and free subscription form that only needs to be completed once--well worth the effort to access their timely and important articles.

Click on title to read the full article.

Palbociclib Delays Breast Cancer Progression in Phase III Trial

April 15, 2015

By Onc Live: Jason M. Broderick and Silas Inman

The PALOMA-3 trial examining a palbociclib regimen in HR+/HER2- breast cancer was halted after an independent panel determined it met the primary endpoint of improving progression-free survival (PFS). The results were announced by Pfizer, the company developing palbociclib, which noted that these are the first randomized phase III data reported for the CDK 4/6 inhibitor.

MBCN NOTE: This is another step closer to having Ibrance approved for 2nd and  3rd line treatment of ER+ resistant disease. Currently Ibrance is approved only for initial treatment.

Top Breast and Ovarian Cancer Research Findings for the Past Year

March 13, 2015

By OncLive

These findings are among the 2014 highlights that Tripathy reviewed in an overview that was the annual feature of the Miami Breast Cancer Conference Feb. 26-Marc -

Breast Cancer Cocktail Buys More Than a Year of Life

February 24, 2015

By Maggie Fox and Maren Shapiro

A cocktail of three breast cancer drugs buys patients an extra 16 months of life — a good news story so unusual, doctors have rushed to make it standard therapy, researchers said Wednesday.

Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan

February 13, 2015

By Journal of Medical Case Reports 2015, 9:5

Pegylated irinotecan NKTR-102 is a topoisomerase I inhibitor-polymer conjugate. This new formulation of irinotecan has been evaluated in a phase II clinical trial and is showing remarkable activity.

New York Attorney General Targets Supplements at Major Retailers

February 5, 2015

By New York Times

GNC, Target, Walgreens and Walmart were accused of selling fraudulent and potentially dangerous herbal supplements and told by New York State officials to stop selling them.

FDA Approves Ibrance for Postmenopausal Women with Advanced Breast Cancer

February 4, 2015

By FDA News Release

The U.S. Food and Drug Administration today granted accelerated approval to Ibrance (palbociclib) to treat advanced (metastatic) breast cancer.

World Cancer Day February 4

February 4, 2015

Taking place under the tagline ‘Not beyond us’, World Cancer Day 2015 will take a positive and proactive approach to the fight against cancer, highlighting that solutions do exist across the continuum of cancer, and that they are within our reach.

Second-Line Everolimus in Metastatic Breast Cancer

February 2, 2015

By Onc Live

Several second-line treatment options exist for patients with ER-positive metastatic breast cancer following progression on frontline therapy.  Also 12 videos with outstanding MBC oncologists about new treatments.

Cancer Drugs Fund: Life-extending drugs to be denied to NHS patients in England as fund overspends

January 19, 2015

By The Independent, Charlie Cooper

Sixteen life-extending cancer drugs will no longer be available to patients in England from March after the NHS announced it would not pay for them through the Government’s flagship Cancer Drugs Fund (CDF).

The drugs have been removed from a list of treatments paid for by the CDF in a bid to cut costs. The £280m fund was due to overspend by £100m in 2014-15.

Panel Laments Lack of Options for Advanced Breast Ca

November 17, 2014

By Medpage Today, Charles Bankhead

The lack of options for advanced breast cancer has created a sense of urgency for high-quality research and clinical trials to address a multitude of unanswered questions, a guideline panel concluded.

Though treatment advances have extended the duration of survival, advanced breast cancer remains almost uniformly fatal. Consequently, the principal goals have been to improve the length and quality of life for patients.

 1 2 3 >  Last ›